Jeung Chanup, Attanasio Laura B, Geissler Kimberley H
Department of Health Policy, Management and Behavior, College of Integrated Health Sciences, State University of New York at Albany, Rensselaer, New York, USA.
Department of Health Promotion and Policy, University of Massachusetts Amherst School of Public Health and Health Sciences, Amherst, Massachusetts, USA.
Health Serv Res. 2025 Apr;60 Suppl 2(Suppl 2):e14420. doi: 10.1111/1475-6773.14420. Epub 2024 Dec 16.
To evaluate the impact of the Massachusetts Medicaid program's reimbursement policy change for perinatal depression screening on utilization rates.
This study employed a difference-in-differences design to compare insurance-paid prenatal and postpartum depression screening rates as well as postpartum antidepressant receipt rates between Medicaid and privately insured individuals before and after policy implementation in May 2016.
Data are from the 2014-2020 Massachusetts All-Payer Claims Database. The study included individuals with a live birth from October 10, 2014, to December 31, 2019, who were continuously insured either by Medicaid or private insurance.
Among 141,085 births, 42.6% were covered by Medicaid. Among those with Medicaid, 1.9% had a paid postpartum depression screening prior to the policy and 16.9% after (1.5% vs. 12.3% for prenatal screening); among privately insured, 3.8% had a paid postpartum screening prior to the policy and 10.6% after (0.9% vs. 6.7% for prenatal screening). Antidepressant receipt rose from 6.9% to 8.3% among Medicaid enrollees and from 3.3% to 4.9% among privately insured individuals after the policy. After regression adjustment, implementation of the Massachusetts Medicaid reimbursement policy was positively associated with perinatal depression screening rates with a differential increase of 10.0 percentage points (p < 0.001) for postpartum screening and 3.5 percentage points (p < 0.001) for prenatal screening among Medicaid enrollees versus privately insured. Despite increased depression screening, the policy was not associated with a statistically significant change in antidepressant receipt among Medicaid enrollees compared to privately insured individuals.
Separate payment for perinatal depression screening significantly improved screening rates among Medicaid beneficiaries, highlighting Medicaid's critical role in identifying mental health needs for vulnerable populations. However, the persistence of sub-optimal screening rates among perinatal individuals underscores the need for a comprehensive approach to ensure universal screening and effective treatment for perinatal depression.
评估马萨诸塞州医疗补助计划对围产期抑郁症筛查的报销政策变化对利用率的影响。
本研究采用双重差分设计,比较2016年5月政策实施前后医疗补助和私人保险参保者的保险支付产前和产后抑郁症筛查率以及产后抗抑郁药的使用率。
数据来自2014 - 2020年马萨诸塞州全支付方索赔数据库。该研究纳入了2014年10月10日至2019年12月31日期间有活产记录、持续参保医疗补助或私人保险的个体。
在141,085例分娩中,42.6%由医疗补助覆盖。在医疗补助参保者中,政策实施前有1.9%进行了付费产后抑郁症筛查,政策实施后为16.9%(产前筛查为1.5%对12.3%);在私人保险参保者中,政策实施前有3.8%进行了付费产后筛查,政策实施后为10.6%(产前筛查为0.9%对6.7%)。政策实施后,医疗补助参保者的抗抑郁药使用率从6.9%升至8.3%,私人保险参保者从3.3%升至4.9%。经过回归调整后,马萨诸塞州医疗补助报销政策的实施与围产期抑郁症筛查率呈正相关,医疗补助参保者产后筛查的差异增加了10.0个百分点(p < 0.001),产前筛查增加了3.个百分点(p < 0.001),与私人保险参保者相比。尽管抑郁症筛查有所增加,但与私人保险参保者相比,该政策并未使医疗补助参保者的抗抑郁药使用率发生统计学上显著的变化。
围产期抑郁症筛查单独付费显著提高了医疗补助受益人的筛查率,凸显了医疗补助在识别弱势群体心理健康需求方面的关键作用。然而,围产期个体筛查率仍未达到最佳水平,这突出表明需要采取综合方法以确保对围产期抑郁症进行普遍筛查和有效治疗。